LDC has invested in ChargePoint, a market leading manufacturer and innovator of specialist high containment and sterile transfer valves. PMSI provided CDD to support the transaction.
ChargePoint manufactures and supplies high-performance containment and sterile transfer valves to the largest global pharmaceutical, bio-pharmaceutical and chemicals companies. Operating across Europe, Asia and North America, its patented technology is used in the development and manufacture of medicines and vaccines by the top 50 global pharmaceutical manufacturers, facilitating the safe transfer of highly-potent and sterile powders.
Following LDC’s investment, the business plans to capitalise on the strong and increasing demand for its solutions internationally, in particular North America, whilst accelerating sales of its innovative AseptiSafe® Bio product and investing in the development of new products, particularly in the aftercare market. The investment from LDC will also enable management to embark on a targeted acquisition strategy to help it expand into adjacent sectors requiring containment and sterile transfer solutions.
Chris Eccles, MD of ChargePoint commented: “We have created a strong platform for future growth and bringing LDC on board as an investment partner is a clear statement of intent regarding our future ambitions. With the team’s track record in the sector and its in-depth experience of delivering international growth, we’re confident we have the right people in place to help us take our market-leading technology even further afield.”
CDD for Apposite Capital's acquisition of 1MED
Apposite Capital, a healthcare specialist private equity investor, has acquired 1MED, a fast-growing Contract Research Organisation (“CRO”) for clinical and ...
CDD for LDC's investment in Omniplex, a market-...
Omniplex, a market-leading eLearning solutions provider, has secured investment from leading mid-market private equity investor LDC to support its growth str...